DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/21a030/neuroblastoma_pi) has announced the addition of Global Markets Direct's new report "Neuroblastoma - Pipeline Review, Q3 2011" to their extensive offering of therapeutic market research publications.
Global Markets Direct's Neuroblastoma - Pipeline Review, Q3 2011 provides information on the therapeutic development for neuroblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for neuroblastoma.
Neuroblastoma - Pipeline Review, Q3 2011 is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Scope:
- A snapshot of the global therapeutic scenario for neuroblastoma.
- A review of the neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the neuroblastoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to Buy:
- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Neuroblastoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned:
- Genzyme Corporation
- United Therapeutics Corporation
- Eli Lilly and Company
- Biotec Pharmacon ASA
- Merck & Co., Inc
- Novartis AG
- Santaris Pharma A/S
- Geron Corporation
- Hana Biosciences, Inc
- Ariad Pharmaceuticals Inc
- Molecular Insight Pharmaceuticals Inc
- Sareum Holdings plc
- Neotropix Inc
- APEIRON Biologics AG
- Archer Biosciences Inc
For more information visit http://www.researchandmarkets.com/research/21a030/neuroblastoma_pi